<SEC-DOCUMENT>0000950170-25-066323.txt : 20250508
<SEC-HEADER>0000950170-25-066323.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508060537
ACCESSION NUMBER:		0000950170-25-066323
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TPG Inc.
		CENTRAL INDEX KEY:			0001880661
		STANDARD INDUSTRIAL CLASSIFICATION:	INVESTMENT ADVICE [6282]
		ORGANIZATION NAME:           	02 Finance
		EIN:				872063362
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93270
		FILM NUMBER:		25923642

	BUSINESS ADDRESS:	
		STREET 1:		301 COMMERCE STREET
		STREET 2:		SUITE 3300
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102
		BUSINESS PHONE:		817-871-4000

	MAIL ADDRESS:	
		STREET 1:		301 COMMERCE STREET
		STREET 2:		SUITE 3300
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TPG Partners, LLC
		DATE OF NAME CHANGE:	20210827

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Temasek Holdings (Private) Ltd
		CENTRAL INDEX KEY:			0001021944
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		60B ORCHARD ROAD #06-18
		STREET 2:		THE ATRIUM@ORCHARD
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			238891
		BUSINESS PHONE:		65 6828 6828

	MAIL ADDRESS:	
		STREET 1:		60B ORCHARD ROAD #06-18
		STREET 2:		THE ATRIUM@ORCHARD
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			238891

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEMASEK HOLDINGS (PRIVATE) LTD
		DATE OF NAME CHANGE:	20050912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEMASEK HOLDINGS LTD
		DATE OF NAME CHANGE:	19960829
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001193125-24-024817</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001021944</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>3</amendmentNo>
      <securitiesClassTitle>Class A Common Stock, par value $0.001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001880661</issuerCik>
        <issuerName>TPG Inc.</issuerName>
        <issuerCusip>872657101</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">301 Commerce Street</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 3300</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Fort Worth</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">TX</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">76102</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Temasek Holdings (Private) Limited</reportingPersonName>
      <citizenshipOrOrganization>U0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>8443225</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>8443225</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>8443225</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>7.2</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
      <comments>Based on 116,946,288 shares of the Issuer's Class A common stock outstanding as of April 8, 2025, as set forth in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the "Commission") on April 23, 2025.

</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Fullerton Management Pte Ltd</reportingPersonName>
      <citizenshipOrOrganization>U0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>3981179</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>3981179</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3981179</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>3.4</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
      <comments>Based on 116,946,288 shares of the Issuer's Class A common stock outstanding as of April 8, 2025, as set forth in the Issuer's definitive proxy statement on Schedule 14A filed with the Commission on April 23, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Temasek Life Sciences Private Limited</reportingPersonName>
      <citizenshipOrOrganization>U0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <sharedVotingPower>3981179</sharedVotingPower>
        <sharedDispositivePower>3981179</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3981179</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>3.4</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
      <comments>Based on 116,946,288 shares of the Issuer's Class A common stock outstanding as of April 8, 2025, as set forth in the Issuer's definitive proxy statement on Schedule 14A filed with the Commission on April 23, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>V-Sciences Investments Pte Ltd</reportingPersonName>
      <citizenshipOrOrganization>U0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>3981179</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>3981179</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3981179</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>3.4</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>Based on 116,946,288 shares of the Issuer's Class A common stock outstanding as of April 8, 2025, as set forth in the Issuer's definitive proxy statement on Schedule 14A filed with the Commission on April 23, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>TPG Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>301 Commerce Street, Suite 3300, Fort Worth, TX 76102</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>(i)	Temasek Holdings (Private) Limited ("Temasek");
(ii)	Fullerton Management Pte Ltd ("Fullerton");
(iii)	Temasek Life Sciences Private Limited ("TLS"); and
(iv)	V-Sciences Investments Pte Ltd ("V-Sciences" and, together with Temasek, Fullerton and TLS, the "Reporting Persons")
</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The address of the principal business office of each Reporting Person is 60B Orchard Road, #06-18, The Atrium@Orchard, Singapore 238891.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>The citizenship of each of the Reporting Persons is the Republic of Singapore.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>As of May 2, 2025, V-Sciences directly owned 3,981,179 shares of the Issuer's Class A common stock. V-Sciences is a wholly-owned subsidiary of TLS, which is a wholly-owned subsidiary of Fullerton, which is a wholly-owned subsidiary of Temasek. Each of TLS, Fullerton and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by V-Sciences.

Temasek, through the ownership described herein and the indirect 100% ownership of two other entities that directly owned an aggregate of 4,462,046 shares of the Issuer's Class A common stock as of May 2, 2025, may be deemed to beneficially own in aggregate 8,443,225 shares of the Issuer's Class A common stock, including the 3,981,179 shares of the Issuer's Class A common stock directly owned by V-Sciences.
</amountBeneficiallyOwned>
        <classPercent>As of May 2, 2025:

Temasek: 7.2%
Fullerton, TLS and V-Sciences: 3.4%

Based on 116,946,288 shares of the Issuer's Class A common stock outstanding as of April 8, 2025, as set forth in the Issuer's definitive proxy statement on Schedule 14A filed with the Commission on April 23, 2025. </classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Temasek: 8,443,225
Fullerton, TLS and V-Sciences: 3,981,179

</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Temasek: 8,443,225
Fullerton, TLS and V-Sciences: 3,981,179

</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Temasek Holdings (Private) Limited</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Jason Norman Lee</signature>
        <title>Jason Norman Lee / Authorized Signatory</title>
        <date>05/08/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Fullerton Management Pte Ltd</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Gregory Tan</signature>
        <title>Gregory Tan / Director</title>
        <date>05/08/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Temasek Life Sciences Private Limited</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Lim Siew Lee Sherlyn</signature>
        <title>Lim Siew Lee Sherlyn / Director</title>
        <date>05/08/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>V-Sciences Investments Pte Ltd</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Han Sack Teng</signature>
        <title>Han Sack Teng / Director</title>
        <date>05/08/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureComments>This statement reports the fact that each of Fullerton, TLS and V-Sciences have ceased to be the beneficial owner of more than 5 percent of the Issuer's Class A common stock. </signatureComments>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
